REDONDO BEACH, CA / ACCESSWIRE / July 21, 2015 / Diabetes affects approximately 387 million people worldwide and that figure is expected to soar to nearly 600 million by 2035, according to the International Diabetes Federation. At the same time, global health expenditures tied to diabetes are expected to surge to nearly a half billion dollars over the coming years, as the world's population ages and puts an increasingly large burden on healthcare systems to cover the costs of treatment.
In this article, we'll take a look at Cell MedX Corp. (OTC: CMXC) and its radically different approach to diabetes treatment that could create an entirely new category in the space.
Patient Zero
In 2014, Cell MedX acquired the rights to key proprietary microcurrent technology targeting the treatment of diabetes and related ailments from co-developers Jean Arnett and Bradley Hargreaves. As a sufferer of Type 1 diabetes herself for more than 40 years, Ms. Arnett had been experimenting with the technology to gauge its safety and efficacy profile firsthand and the team quickly came to realize its tremendous potential within the market.
Click To Sign Up For Future Email Updates On Cell MedX Corp.
As patient zero for the new technology, Ms. Arnett reported A1C levels that fell from 10.7 to 7.6 and insulin sensitivity levels that increased 60%. These significant developments enabled her to cut her insulin requirements in half, while realizing additional benefits like lower blood pressure, less diabetic neuropathy, and fewer diabetic wound issues. In addition, these benefits were realized without any apparent negative side-effects.
While a single patient certainly doesn't prove anything from a rigorous scientific perspective, Ms. Arnett's experience does show an extraordinary degree of personal commitment, dedication and belief in the technology, which is truly an invaluable consideration among the executive officers and directors of a public company. The initial data also instills confidence - especially in terms of a safety profile - when compared to completely untested technologies that offer theoretical solutions, but may be years and millions of dollars away from human trials.
Improving Efficacy
Cell MedX's eBalance technology represents a major departure from current approaches to diabetes treatment. Given that there hasn't been any really new diabetes treatment developed since the creation of insulin, and that virtually all diabetes sufferers rely on extremely frequent injections of the drug, Cell MedX appears to be poised to positively impact individual dosage requirements while improving overall outcomes of insulin-based treatment protocols.
By using physical energy to alter metabolic pathways, the Cell MedX eBalance technology is reported to affect changes in blood sugar disposition which has so far shown to measurably enhance existing treatments. Currently, the technology is being applied for just 20 minutes three times weekly to demonstrate the onset of positive effects.
As a result of the preliminary trials and in relatively short order since its founding, Company management recently announced the commencement of a series of clinical trials aimed at moving the technology ahead in order to realize their ambitious quest for an affordable and readily available medical device designed specifically for home care use as part of the Company's ultimate commercialization strategy.
Watch a Q&A video with CMXC CEO Frank McEnulty and Chief Medical Officer John Sanderson, MD
By contrast, most new approaches in the diabetes sector are focused exclusively pharmaceutical solutions aimed at making insulin delivery less reliant on injections. MannKind Corporation (NASDAQ: MNKD) has reached a $2.2 billion valuation due in large part to its Afrezza technology - an inhaled insulin used to control high blood sugar. Novo Nordisk A/S (NYSE: NVO) has also introduced an easy-to-use insulin tablet, although the product only accounts for a small fraction of its $121 billion market capitalization.
In the small-cap space, Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) is working on an orally ingestible insulin capsule that's in Phase II clinical trials, taking the same approach to insulin delivery as many larger competitors. Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) is taking a bit of a different approach with its dual inhibitor of sodium-glucose transporters 1 and 2, with plans to initiate clinical trials this year targeting Type 1 diabetes.
Fast & Low-Cost
Cell MedX has already started recruiting 30 Type 1 and Type 2 diabetic patients for its Phase II-A clinical trial in Orange County, California. Over the next six to eight months, the company medical team will carefully study clinical endpoints including the reduction in HbA1C levels independent of other factors. The clinical trials will also continue to assess how metabolic changes and pathways lead to improved glycemic control and to determine optimal parameters and settings for the technology.
At the same time, management is working on early stage steps towards the development of a commercially practicable prototype device for use in subsequent trials. The prototype would include refined electronic circuitry, hardware and software optimized to the most effective parameters. Preliminary design considerations are focused with the user in mind in order to simplify, mobilize, and create a pleasurable user experience based on ease of use and convenience.
The company's experience with the technology to-date suggests that it has a robust safety profile that could translate to rapid industry approval. Unlike the pharmaceutical cousins mentioned earlier in the article, this adjunct technology won't require millions of dollars and decades of trials to achieve a market launch target date, as so-called 510(k) devices are often approved at a fraction of the cost and time than pharmaceutical drugs.
Looking Ahead
Cell MedX has an exciting future ahead as it brings its innovative eBalance technology into the design, development, trial and prototyping pathway towards industry approval and market launch. With its upcoming clinical trials underway, investors can expect to see a steady stream of potentially market-moving news, while all early indications are pointing to robust efficacy and safety profiles that suggest these trials hold the potential to offer diabetes sufferers an entirely new class of treatment. And with a focus on diabetes, there is no shortage of demand for an alternative solution to what is a seemingly endless growth market.
For more information, visit the company's website at www.cellmedx.com.
Click To Sign Up For Future Email Updates On Cell MedX Corp.
http://www.tdmfinancial.com/emailassets/cmxc/cmxc_landing.php
Legal Disclaimer:
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx.
SOURCE: Emerging Growth LLC
